methamphetamine has been researched along with rimcazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sonsalla, PK; Terleckyj, I | 1 |
| Atluri, VSR; Jayant, RD; Kaushik, A; Nair, M; Pilakka-Kanthikeel, S; Tiwari, S; Yndart, A | 1 |
2 other study(ies) available for methamphetamine and rimcazole
| Article | Year |
|---|---|
The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain Diseases; Butaclamol; Carbazoles; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Interactions; Drug Synergism; Guanidines; Ligands; Male; Methamphetamine; Mice; MPTP Poisoning; Neostriatum; Piperidines; Psychotropic Drugs; Pyrimidines; Receptors, Dopamine; Receptors, sigma; Stereoisomerism; Tyrosine 3-Monooxygenase | 1994 |
Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS.
Topics: AIDS Dementia Complex; Astrocytes; Blood-Brain Barrier; Carbazoles; Cocaine; Delayed-Action Preparations; Endothelial Cells; HIV Protease Inhibitors; HIV-1; Humans; Illicit Drugs; Magnets; Methamphetamine; Nanostructures; Nelfinavir; Neuroprotective Agents; Primary Cell Culture; Substance Abuse, Intravenous | 2017 |